Showing 181 - 200 results of 66,474 for search '(( e point decrease ) OR ((( 5 we decrease ) OR ( 5 ((nn decrease) OR (a decrease)) ))))', query time: 1.14s Refine Results
  1. 181
  2. 182
  3. 183

    Table_2_Decrease in COVID-19 adverse outcomes in adults during the Delta and Omicron SARS-CoV-2 waves, after vaccination in Mexico.docx by Lenin Domínguez-Ramírez (481547)

    Published 2022
    “…In this scenario of high SARS-CoV-2 circulation, we analyzed the effectiveness of the country's vaccination strategy that used 7 different vaccines from around the world, and focused on vaccinating the oldest population first. …”
  4. 184

    Table_1_Decrease in COVID-19 adverse outcomes in adults during the Delta and Omicron SARS-CoV-2 waves, after vaccination in Mexico.docx by Lenin Domínguez-Ramírez (481547)

    Published 2022
    “…In this scenario of high SARS-CoV-2 circulation, we analyzed the effectiveness of the country's vaccination strategy that used 7 different vaccines from around the world, and focused on vaccinating the oldest population first. …”
  5. 185
  6. 186
  7. 187
  8. 188

    Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d’Ivoire: A model-based analysis by Eric N. Ouattara (6890174)

    Published 2019
    “…</p><p>Methods</p><p>We used a mathematical model to compare three potential ART initiation criteria: 1) CD4 <350/μL (<i>ART<350/μL</i>); 2) CD4 <500/<i>μ</i>L (<i>ART<500/μL</i>); and 3) ART at presentation (<i>Immediate ART</i>). …”
  9. 189
  10. 190
  11. 191
  12. 192

    HFD induces LDs and decreases ER and mitochondria in nephrocytes. by Aleksandra Lubojemska (10746241)

    Published 2021
    “…(<b>E</b>) Low and high magnification views of pericardial nephrocytes (dotted outlines) from STD and HFD larvae, showing that HFD decreases mitochondria (marked with anti-ATP5A) and ER (marked with anti-KDEL) but increases LDs (marked with LipidTOX). …”
  13. 193
  14. 194

    The combination of LPS and PFC caused faster clot initiation and decreased clot strength. by Heather F. Pidcoke (9023789)

    Published 2022
    “…By RM ANOVA, the time effects were obscured by interaction with group: SAL-SAL, p = NS; LPS-SAL, MA increases with time; T0 v T72 and T96, p≤0.05; SAL-PFC: MA drops @ T96, p≤0.05; LPS-PFC: T0 v all others, p≤0.05 with a recovery at T96, (p≤0.05 compared to T72); SAL-PFC: no significant change, p = NS. …”
  15. 195

    Table_1_v2_A long waiting time from diagnosis to treatment decreases the survival of non-small cell lung cancer patients with stage IA1: A retrospective study.docx by Bin Liu (5899)

    Published 2022
    “…After adjusting for other confounders, the waiting time was identified as an independent prognostic factor.</p>Conclusions<p>A long waiting time before treatment may decrease the survival of stage IA1 NSCLC patients. …”
  16. 196
  17. 197
  18. 198

    Image4_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

    Published 2024
    “…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”
  19. 199

    Image2_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

    Published 2024
    “…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”
  20. 200

    Image6_Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition.jpeg by Mohammad Arif Rahman (8267352)

    Published 2024
    “…<p>SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. …”